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BP measurements and 24 ‑hour ambulatory BP 
monitoring (ABPM).
The research hypothesis assumes that the im‑
plementation of complex coordinated cardio‑
‑oncological care using the “ON ‑CARDIO’’ pro‑
gram will help achieve cardio ‑oncological pre‑
vention goals, determine the demand for cardio‑
‑oncological interventions, and contribute to 
the early detection of cardiac complications, in‑
cluding arrhythmias, thus potentially improving 
prognosis in BC patients.
Patients and methods The study group will include 
200 patients with newly diagnosed BC, recruit‑
ed prior to commencing oncological treatment. 
The follow ‑up will last 12 months.
The inclusion criteria are as follows: informed 
consent, age of 18 years or older, new diagno‑
sis of BC, planned anticancer therapy, life ex‑
pectancy exceeding 12 months, and stable con‑
dition enabling performance of planned tests, 
regardless of cancer stage. The exclusion crite‑
ria include pregnancy, history of atrial fibrilla‑
tion (AF), and lack of the patient’s or family’s 
ability to use a smartphone necessary for ECG 
telemonitoring.
The study was approved by a local bioethics 
committee. Prior to randomization, each patient 
will undergo laboratory testing (N ‑terminal pro‑
‑B‑type natriuretic peptide, troponin, C ‑reactive 
protein, hemoglobin A1c, lipid profile) and baseline 
measurements including BP, heart rate, weight, 
height, waist circumference, and echocardiogra‑
phy. Patients will then be randomized in a 1:1 ra‑
tio either to an intervention arm or a standard‑
‑care arm.
Introduction Cardiovascular (CV) disease and 
cancer constitute the main causes of death in 
the modern world, and every effort should be 
made to reduce these negative trends.1,2 Breast 
cancer (BC) is the most common malignancy in 
women, both in Poland and across Europe, and 
remains the leading cause of cancer ‑related death. 
The most significant risk factors for BC include ge‑
netic predisposition, exposure to estrogens, ion‑
izing radiation, and low parity. Interestingly, BC 
also shares significant risk factors with CV dis‑
ease, such as the Western ‑style diet, obesity, age, 
and alcohol consumption.3
The aim of this study is to develop a cardio‑
‑oncological care program, “ON ‑CARDIO,” for 
patients with BC.4 Specifically, the study aims 
to investigate: 1) whether the introduction of 
the “ON ‑CARDIO” telemedicine care program 
will improve the attainment of CV prevention 
goals as set out in current European guidelines; 
2) the type and number of cardio ‑oncological in‑
terventions; 3) arrhythmia frequency and rela‑
tionship with oncological therapy (via electrocar‑
diogram [ECG] telemonitoring using the Alive‑
Cor Kardia Mobile EKG application [Alive Cor 
Inc, Mountain View, California, United States]); 
4) the relationship between cardio ‑oncological 
interventions, control of CV risk factors, and 
the rate of CV complications in patients with 
BC; 5) the influence of cardio ‑oncological inter‑
ventions on various predetermined biochemis‑
try parameters; 6) the influence of oncological 
therapy in BC on left ventricular function as‑
sessed by echocardiography, potential arrhyth‑
mia assessed by ECG and 24 ‑hour Holter mon‑
itoring, blood pressure (BP) assessed by office 
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at 1, 6, and 12 months: echocardiography, ECG, 
24 ‑hour Holter monitoring, ABPM; assessment 
of Eastern Cooperative Oncology Group perfor‑
mance status; assessment of the quality of life 
according to the European Organization for Re‑
search and Treatment of Cancer questionnaire; 
and 6 ‑minute walk test; 3) participation in ECG 
telemonitoring over the first 6 months aiming 
at AF screening (following appropriate training 
in the use of the Alive Cor application).
Standard ‑care arm Following randomization, pa‑
tients will remain over 12 months under standard 
care. At the end of the study period, the groups 
will be compared regarding the number of re‑
ceived cardio ‑oncological interventions, cardiac 
complications over the last 12 months, and CV 
test results, as shown in FIGURE 1.
Statistical analysis Baseline characteristics of 
participants will be compared with the χ2 test, 
Intervention arm Following enrollment, 15 fac‑
tors will be assessed and recorded using the “ON‑
‑CARDIO” program, installed on dedicated tab‑
lets used for periodic reassessment of the follow‑
ing factors during the study: 1) factors associat‑
ed with prevention (physical activity, diet, obesi‑
ty, smoking, alcohol); 2) factors associated with 
vital parameters (BP, heart rate); and 3) factors 
associated with treatment (ECG, cardioprotec‑
tive therapy, anticoagulant therapy, hypoglyce‑
mic therapy, lipid ‑lowering therapy, psychother‑
apy, alternative paramedical anticancer therapy, 
and AliveCor compliance).
Patients in the intervention arm will under‑
go coordinated cardio‑oncological training that 
will encompass: 1) participation in 6 educational 
workshops over the first 6 months, delivered by 
qualified nurses, dieticians, physiotherapists, and 
psychologists. They will also be provided with in‑
struction on how to perform home ‑based exercis‑
es; 2) the following investigations at baseline and 
FIGURE 1 Study design 
Abbreviations: ABPM, ambulatory blood pressure monitoring; ECOG, Eastern Cooperative Oncology Group performance status; EORTC, European 
Organisation for Research and Treatment of Cancer; 6MWT, 6 ‑minute walk test
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In recent years, there has been a significant 
expansion in the use of telemedicine to im‑
prove safety and efficacy of treatment as well 
as to improve patient education.10 Currently, 
in oncology, the use of telemedicine is focused 
on the decision ‑making process and on remote 
monitoring of symptoms in palliative patients.11 
We are unaware of any current attempts to use 
telemedicine in preventive care, such as screen‑
ing for arrhythmias, in oncological patients, al‑
though they have a considerable risk of arrhyth‑
mias during oncological therapy.
This BREAST ‑AID study will address these un‑
answered questions and contribute to the devel‑
opment of telemedicine and preventive care in 
patients with BC.4
The implementation of managed care pro‑
grams has had notable success in Poland, for 
example, in patients after myocardial infarc‑
tion.12 Managed care programs are soon to be 
implemented also in other areas, such as in pa‑
tients with heart failure or in oncology. Given 
the increased incidence of CV risk factors in pa‑
tients with BC, as well as the evidence indicat‑
ing increased CV mortality in cancer survivors, 
we believe this group of patients stand to bene‑
fit from coordinated cardio ‑oncological care pro‑
grams. The development of the “ON ‑CARDIO” 
program in BC patients might provide the basis 
for similar care programs in patients diagnosed 
with different cancers in the future.
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Discussion Both preventing CV disease in BC 
patients and reducing the risk of cardiac compli‑
cations of anticancer therapy are highly signifi‑
cant goals.1 Published evidence suggests that CV 
disease is the major cause of competing mortal‑
ity in women with BC, and that women with BC 
have higher CV risk than those without.5 How‑
ever, this increased risk may be partially due 
to the side effects of anticancer medication, as 
CV prevention programs are rarely implement‑
ed in oncological patients.6 As a result, we know 
little about the efficacy of risk ‑reduction pro‑
grams in this population. We do know, howev‑
er, from large European preventive cardiology 
programs such as EUROACTION, that lifestyle 
changes and risk factor reduction can have sig‑
nificant positive impact on individuals’ health 
both in primary and secondary prevention of 
CV diseases.7 Therefore, we aim to investigate 
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To date, ECG telemonitoring has not been used 
in patients undergoing treatment for BC. Howev‑
er, their disease and the complex nature of their 
care predisposes them to arrhythmias.
The relationship between BP and BC treat‑
ment is complex. Elevated BP is of course a ma‑
jor risk factor for CV disease, and poor BP con‑
trol may increase the risk of cardiotoxicity from 
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